Atlas Trials

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Clinical trial NCT04629248 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04629248
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Membranous Nephropathy
Start date
2021-06-25
Primary completion
2025-12-22
Enrollment
142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.